Sai Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 25.00 Cr
- Paid Up Capital ₹ 19.07 Cr
- Company Age 26 Year, 28 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1,137.73 Cr
- Satisfied Charges ₹ 1,364.72 Cr
- Revenue Growth 11.61%
- Profit Growth -75.99%
- Ebitda -24.79%
- Net Worth 2.71%
- Total Assets 15.93%
About Sai Life Sciences
Sai Life Sciences Limited (SLSL) is a leading Public Limited Indian Non-Government Company incorporated in India on 25 January 1999 and has a history of 26 years. Its registered office is in Rangareddy, Telangana, India.
The Corporate was formerly known as Sai Life Sciences Limited Definitions & Interpretation. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 25.00 Cr and a paid-up capital of Rs 19.07 Cr.
The company currently has active open charges totaling ₹1,137.73 Cr. The company has closed loans amounting to ₹1,364.72 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Sai Life Sciences Limited India are Runa Karan as Company Secretary, Lakshminarayanan Chittor as Cfo, Krishnamraju Kanumuri as Ceo, and One other members. Ranga Kanumuri, Krishnamraju Kanumuri, Ramesh Iyer, and Three other members serve as directors at the Company.
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24110TG1999PLC030970
- Company No.
030970
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
25 Jan 1999
- Date of AGM
14 Jun 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Sai Life Sciences Limited offer?
Sai Life Sciences Limited offers a wide range of products and services, including Pharmaceutical Services, Molecular Biology Services, Pharma & Bioanalytical Services, Medicinal Chemistry Services, Formulation Development Service, Life Science Service, Medical Consultancy Services, Microbiology Services.
Who are the key members and board of directors at Sai Life Sciences?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishnamraju Kanumuri  | Managing Director | 01-Oct-2010 | Current |
| Runa Karan | Company Secretary | 03-Oct-2008 | Current |
Lakshminarayanan Chittor  | CFO | 01-Jul-2021 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ranga Kanumuri | Whole-Time Director | 25-Jan-1999 | Current |
| Ramesh Iyer | Director | 21-May-2024 | Current |
| Rajagopal Tatta | Director | 10-Jan-2007 | Current |
| Mitesh Daga | Director | 30-Jul-2018 | Current |
| Suchita Sharma | Director | 10-Jun-2024 | Current |
Financial Performance of Sai Life Sciences.
Sai Life Sciences Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 11.61% increase. The company also saw a substantial fall in profitability, with a 75.99% decrease in profit. The company's net worth moved up by a moderate rise of 2.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sai Life Sciences?
In 2022, Sai Life Sciences had a promoter holding of 37.95% and a public holding of 62.05%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nbs International LimitedRamesh Iyer is a mutual person
Tvs Capital Funds Private LimitedRamesh Iyer is a mutual person
Mahindra Agri Solutions LimitedRamesh Iyer is a mutual person
Ranmyt Trading Private LimitedRanga Kanumuri is a mutual person
- Sai Life Pharma Private Limited
Ranga Kanumuri, Krishnamraju Kanumuri and 4 more are mutual person
Mahindra First Choice Wheels LimitedRamesh Iyer is a mutual person
Charges (Loans)
₹1,137.73 Cr
₹1,364.72 Cr
Charges Breakdown by Lending Institutions
- Sbicap Trustee Company Limited : 1137.73 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹768.60 Cr | Open |
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹25.00 Cr | Open |
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹18.76 Cr | Open |
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹11.39 Cr | Open |
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹75.00 Cr | Open |
How Many Employees Work at Sai Life Sciences?
Sai Life Sciences has a workforce of 2845 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sai Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sai Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
